Methods of treating tumors

Details Methods of treating tumors Methods of treating tumors

2006-02-07

2006-02-07

Low, Christopher S. F. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S263320, C514S269000, C514S222500, C424S054000, C424S085100, C424S195110, C424S246100

Reexamination Certificate

active

06995164

ABSTRACT:
The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.

REFERENCES:
patent: 3423408 (1969-01-01), Pfirrmann
patent: 3963706 (1976-06-01), Pfirrmann
patent: 4096241 (1978-06-01), Geistlich et al.
patent: 4107305 (1978-08-01), Pfirrmann
patent: 4226858 (1980-10-01), Pfirrmann
patent: 4337251 (1982-06-01), Pfirrmann
patent: 4587268 (1986-05-01), Geistlich
patent: 4604391 (1986-08-01), Pfirrmann
patent: 4626536 (1986-12-01), Pfirrmann
patent: 4772468 (1988-09-01), Pfirrmann
patent: 5210083 (1993-05-01), Pfirrmann
patent: 5573771 (1996-11-01), Geistlich et al.
patent: 5593665 (1997-01-01), Pfirrmann et al.
patent: 5819748 (1998-10-01), Pfirrmann
patent: 5954687 (1999-09-01), Baudino
patent: 5972933 (1999-10-01), Pfirrmann
patent: 5976822 (1999-11-01), Landrum et al.
patent: 6011030 (2000-01-01), Pfirrmann
patent: 6080397 (2000-06-01), Pfirrmann et al.
patent: 6117868 (2000-09-01), Pfirrmann
patent: 6303596 (2001-10-01), Morrissey et al.
patent: 6429224 (2002-08-01), Calabresi et al.
patent: 6448030 (2002-09-01), Rust et al.
patent: 6465448 (2002-10-01), Gerson et al.
patent: 6670330 (2003-12-01), Lampidis et al.
patent: 6703413 (2004-03-01), Calabresi et al.
patent: 0253662 (1988-01-01), None
patent: 1066830 (2001-01-01), None
patent: WO 90/06138 (1990-05-01), None
patent: WO 91/13628 (1991-09-01), None
patent: WO 92/00743 (1992-01-01), None
patent: WO 94/03174 (1994-02-01), None
patent: WO 98/52572 (1998-11-01), None
patent: WO 99/06114 (1999-02-01), None
patent: WO 99/34805 (1999-07-01), None
Fiebig et al, “Relevance of Tumor Models for Anticancer Drug Development”, Contrib. Oncol. Basel. Karger, vol. 54, pp. 109-120.
Blenkharn et al. (1987) “The Antibacterial and Anti-Endotoxin Activity of Taurolidine in Combination with Antibiotics,” Surg. Res. Commun., 2:149-155.
Browne M.K. et al. (1985) “Studies on the Antiendotoxin Properties of Taurolin in Animals and Man,”Recent Advances in Chemotherapy, Proceedings of the 14thInternational Congress of Chemotherapy, Kyoto, pp. 2075-2076.
Browne M.K. et al. (1976) “Taurolin, a New Chemotherapeutic Agent,”The Journal of Applied Bacteriology, vol. 41, pp. 363-368.
Geistlich Catalog, “Taurolin, Triad antimicrobial chemotherapy” pp. 1-95, (1982).
Gormans et al. (1987) “Reduced Adherence of Micro -Organisms to Human Mucosal Epithelial Cells Following Treatment with Taurolin, a Novel Antimicrobial Agent,” J. App. Bacteriol., 62:315-320.
Hamik, A. et al. (1997) “Taurolidine Inhibits Tissue Factor Expression in Monocytes,”Abstract from the XVIth Congress of the International Society on Thrombosis and Haemostasis, Florence, Jun. 6-12.
Jacobi, C. et al. (1999) “New Therapeutic Strategies to Avoid Intra- and Extraperitoneal Metastases during Laparoscopy: Results of a Tumor Model in the Rat,”Digestive Surgery, vol. 16 (5), pp. 393-399.
Jacobi, C. et al. (1997) “Inhibition of Peritoneal Tumor Cell Growth and Implantation in Laparoscopic Surgery in a Rat Model,”The American Journal of Surgery, vol. 174 (3), pp. 359-363.
Jacobi, C. et al. (1999) “Influence of Different Gases and Intraperitoneal Instillation of Antiadherent of Cytotoxic Agents on Peritoneal Tumor Cell Growth and Implantation with Laproscopic Surgery in a Rat Model,”Surg. Endos.13:1021-25.
Knight et al., (1983) “NMR Studies and GC Analysis of the Antibacterial Agent Taurolidine,” J. Pharm. Sci. 72:705-707.
Leaper et al. (1985) “Prevention of peritoneal adhesions after thermal injury using the formaldehyde carriers noxythidin and Taurolin”,Br. Soc. Gastroenterology, p. A901.
McCourt, M. et al. (2000) “Taurolidine Inhibits Tumor Cell Growth In Vitro and In Vivo,”Annals of Surgical Oncology, vol.. 7(9), pp. :685-691.
Monson, J.R.T. et al. (1990) “Preliminary evidence that taurolidine is anti-neoplastic as well as anti-endotoxin and anti-microbial,”The British Journal of Surgery, vol. 77(6), pp. 711.
Monson, J.R.T. et al. (1990) “Taurolidine as an anti-neoplastic agent: a previously undiscovered role?”The British Journal of Surgery, vol. 77(12).
Monson, J.R.T. et al., (1993) “Taurolidine inhibits tumor necrosis factor (TNF) toxicity new evidence of TNF and endotoxin synergy,”European Journal of Surgical Oncology, 19:226-231.
Reymond, M.A. et al. (2000) “Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator,”Surgical Endoscopy, vol. 14(1), pp. 51-55.
Umpleby, H. et al. (1984) “The efficacy of agents employed to prevent anastomotic recurrence in colorectal carcinoma,”Annals of the Royal College of Surgeons of England, 66:192-194.
Volz J. et al. (2000) “Modulation of Tumor-Induced Lethality after Pneumoperitoneum in a Mouse Model,”Cancer, vol. 89(2), pp. 262-266.
Wicki, O. et al, (1983) “Solution for Surgical Lavage,”Langenbecks Archiv für Chirurgie, p. 778, Abstract 276.
International Search Report for PCT/US00/33103, mailed Dec. 3, 2001.

Affiliated with

Also associated with

Rating

Methods of treating tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating tumors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3661036